Rafael launches Phase III trial of pancreatic cancer drug
Rafael Pharmaceuticals has commenced the Phase III AVENGER 500 trial to examine CPI-613 (devimistat) in combination with modified folfirinox (mFFX)…
Rafael Pharmaceuticals CPI-613 folfirinox
